Overview

89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)

Status:
Recruiting
Trial end date:
2022-09-11
Target enrollment:
Participant gender:
Summary
The main purposes of this study include: Looking at the way the body absorbs, distributes, and gets rid of 89Zr-DFO-REGN3767 Finding the best dose amount of 89Zr-DFO-REGN3767 Finding the best time for PET scanning after injection of 89Zr-DFO-REGN3767
Phase:
Early Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center